Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects With de Novo Native Coronary Artery Lesions

Next Previous
Trial Profile

A Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects With de Novo Native Coronary Artery Lesions

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Everolimus (Primary)
  • Indications Coronary artery restenosis
  • Focus Therapeutic Use
  • Acronyms ABSORB IV
  • Sponsors Abbott Vascular

Most Recent Events

  • 13 May 2023 Results assessing the long term (5-year) clinical outcomes, published in the Journal of the American College of Cardiology.
  • 08 Jul 2022 Status changed from active, no longer recruiting to completed.
  • 24 Sep 2019 Planned primary completion date changed from 1 Sep 2017 to 1 Apr 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top